US Stock MarketDetailed Quotes

EIGRQ Eiger BioPharmaceuticals

Watchlist
  • 8.500
  • 0.0000.00%
15min DelayTrading Sep 27 16:00 ET
12.59MMarket Cap-724P/E (TTM)

About Eiger BioPharmaceuticals Company

Eiger BioPharmaceuticals Inc is a commercial stage biopharmaceutical company focused on the development and commercialization of drugs for serious, rare, and ultra-rare diseases with high unmet medical needs and no approved therapies. Its program lonafarnib, a prenylation inhibitor, boosted with ritonavir, for the treatment of Hepatitis Delta Virus (HDV) infection, is in Phase 3 clinical development. Its product candidate pipeline includes Lonafarnib (LNF) in HDV, Peginterferon Lambda (lambda) in HDV, LNF in Progeria, and Progeroid Laminopathies (PL), Avexitide in Post-Bariatric Hypoglycemia (PBH), and Avexitide in Congenital Hyperinsulinism (CHI), all advancing toward Phase 3.

Company Profile

SymbolEIGRQ
Company NameEiger BioPharmaceuticals
CEODr. David Apelian, M.D.,PhD
MarketPink Market
Employees25
Fiscal Year Ends12-31

Company Executives

  • Name
  • Position
  • Salary
  • Dr. David Apelian, M.D.,PhD
  • Director and Chief Executive Officer
  • 204.39K
  • James Vollins
  • General Counsel, Chief Compliance Officer and Corporate Secretary
  • --
  • William G. Kachioff
  • Chief Financial Officer and Principal Accounting Officer
  • --
  • Michelle Maynard
  • Senior Vice President, Finance
  • --
  • Dr. Thomas J. Dietz, PhD
  • Chairman of the Board
  • 274.58K
  • Kim Sablich
  • Independent Director
  • 124.59K
  • Dr. Evan Loh, M.D.
  • Independent Director
  • 137.09K
  • Amit K. Sachdev, J.D.
  • Independent Director
  • 135.09K
  • Lisa Kelly-Croswell
  • Independent Director
  • 181.07K

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
US
Overall
Symbol
Latest Price
% Chg

No Data